Annual report
4151.TEDINET S100XPTY
Period2025-01-01 → 2025-12-31
Filed2026-03-10
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 155
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥496.8bn | 2025-01-01 → 2025-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥495.6bn | 2024-01-01 → 2024-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥442.2bn | 2023-01-01 → 2023-12-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥398.4bn | 2022-01-01 → 2022-12-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥352.2bn | 2021-01-01 → 2021-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Profit before tax | ¥87.2bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥83.5bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥97.2bn | 2023-01-01 → 2023-12-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥67.6bn | 2022-01-01 → 2022-12-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥60.0bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥67.0bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥59.9bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥81.2bn | 2023-01-01 → 2023-12-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥53.6bn | 2022-01-01 → 2022-12-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥52.3bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥67.0bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥59.9bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss IFRS |
| Total assets | ¥1.11T | at 2025-12-31 | Cons. | Assets IFRS |
| Total assets | ¥1.07T | at 2024-12-31 | Cons. | Assets IFRS |
| Total assets | ¥1.03T | at 2023-12-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥939.9bn | at 2022-12-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥921.9bn | at 2021-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥214.5bn | at 2025-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥216.6bn | at 2024-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥893.3bn | at 2025-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥850.8bn | at 2024-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥836.4bn | at 2023-12-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥893.3bn | at 2025-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥850.8bn | at 2024-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥836.4bn | at 2023-12-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥762.8bn | at 2022-12-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥737.2bn | at 2021-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥218.8bn | at 2025-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥244.7bn | at 2024-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥403.1bn | at 2023-12-31v | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥339.2bn | at 2022-12-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥335.1bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥96.6bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥67.9bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥115.6bn | 2023-01-01 → 2023-12-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥48.7bn | 2022-01-01 → 2022-12-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥86.5bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥89.2bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥142.4bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥20.4bn | 2023-01-01 → 2023-12-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥17.2bn | 2022-01-01 → 2022-12-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥11.4bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥36.9bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥84.7bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥32.5bn | 2023-01-01 → 2023-12-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥29.0bn | 2022-01-01 → 2022-12-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥28.4bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥128.07 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥113.06 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥151.03 | 2023-01-01 → 2023-12-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥99.68 | 2022-01-01 → 2022-12-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥97.43 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥128.07 | 2025-01-01 → 2025-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥113.06 | 2024-01-01 → 2024-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥151.01 | 2023-01-01 → 2023-12-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥99.66 | 2022-01-01 → 2022-12-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥97.39 | 2021-01-01 → 2021-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,706.5 | at 2025-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,625.68 | at 2024-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,555.81 | at 2023-12-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,419.27 | at 2022-12-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,371.9 | at 2021-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 80.6% | at 2025-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 79.7% | at 2024-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 81.5% | at 2023-12-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 81.2% | at 2022-12-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 80.0% | at 2021-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 7.7% | 2025-01-01 → 2025-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 7.1% | 2024-01-01 → 2024-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 10.2% | 2023-01-01 → 2023-12-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 7.1% | 2022-01-01 → 2022-12-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 7.3% | 2021-01-01 → 2021-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 5,161 | at 2025-12-31 | Cons. | Number of employees |
| Employees | 5,669 | at 2024-12-31 | Cons. | Number of employees |
| Employees | 5,974 | at 2023-12-31v | Cons. | Number of employees |
| Employees | 5,982 | at 2022-12-31v | Cons. | Number of employees |
| Employees | 5,752 | at 2021-12-31d | Cons. | Number of employees |
| Revenue | ¥297.3bn | 2025-01-01 → 2025-12-31 | Standalone | Net sales |
| Revenue | ¥286.5bn | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥277.2bn | 2023-01-01 → 2023-12-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥253.8bn | 2022-01-01 → 2022-12-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥237.6bn | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥60.0bn | 2025-01-01 → 2025-12-31 | Standalone | Operating income |
| Operating income | −¥4.6bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Ordinary income | ¥56.9bn | 2025-01-01 → 2025-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥68.6bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥67.2bn | 2023-01-01 → 2023-12-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥37.3bn | 2022-01-01 → 2022-12-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥35.2bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥42.3bn | 2025-01-01 → 2025-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥54.4bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Net income | ¥32.4bn | 2025-01-01 → 2025-12-31 | Standalone | Profit loss |
| Net income | ¥60.7bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | ¥50.4bn | 2023-01-01 → 2023-12-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥31.0bn | 2022-01-01 → 2022-12-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥66.4bn | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥808.5bn | at 2025-12-31 | Standalone | Assets |
| Total assets | ¥797.9bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥869.6bn | at 2023-12-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥806.1bn | at 2022-12-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥794.1bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥193.6bn | at 2025-12-31 | Standalone | Liabilities |
| Total liabilities | ¥184.9bn | at 2024-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥614.9bn | at 2025-12-31 | Standalone | Net assets |
| Net assets / equity | ¥613.0bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥622.7bn | at 2023-12-31v | Standalone | Net assets |
| Net assets / equity | ¥601.9bn | at 2022-12-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥596.9bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥7.9bn | at 2025-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥15.7bn | at 2024-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥61.97 | 2025-01-01 → 2025-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥114.57 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥93.7 | 2023-01-01 → 2023-12-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥57.77 | 2022-01-01 → 2022-12-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.52 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥61.97 | 2025-01-01 → 2025-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥114.57 | 2024-01-01 → 2024-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥93.69 | 2023-01-01 → 2023-12-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥57.75 | 2022-01-01 → 2022-12-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥123.47 | 2021-01-01 → 2021-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥62 | 2025-01-01 → 2025-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥58 | 2024-01-01 → 2024-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥56 | 2023-01-01 → 2023-12-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥51 | 2022-01-01 → 2022-12-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥46 | 2021-01-01 → 2021-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,174.53 | at 2025-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,171.3 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,158.1 | at 2023-12-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,119.48 | at 2022-12-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,110.13 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 76.1% | at 2025-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.8% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.6% | at 2023-12-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.6% | at 2022-12-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.1% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 5.3% | 2025-01-01 → 2025-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.8% | 2024-01-01 → 2024-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2023-01-01 → 2023-12-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.2% | 2022-01-01 → 2022-12-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.1% | 2021-01-01 → 2021-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 525,634,500 | at 2025-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 525,634,500 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 540,000,000 | at 2023-12-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 540,000,000 | at 2022-12-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 540,000,000 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 3,503 | at 2025-12-31 | Standalone | Number of employees |
| Employees | 4,013 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 4,082 | at 2023-12-31v | Standalone | Number of employees |
| Employees | 4,002 | at 2022-12-31v | Standalone | Number of employees |
| Employees | 3,857 | at 2021-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 2
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceuticalsreportable segment | employees | at 2025-12-31 | 5161 pure |
| Pharmaceuticalsreportable segment | employees | at 2025-12-31 | 3503 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,910
| Item | Context | Value | Unit |
|---|---|---|---|
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 1.108 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.897 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 0.919 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.994 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.127 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.100 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.411 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.699 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 2.132 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E00816-000PharmaceuticalsReportableSegmentMember | 5161 | |
| Number of employees | CurrentYearInstant | 5161 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 3503 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 42.4 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 15.5 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 9866204 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00816-000PharmaceuticalsReportableSegmentMember | 3503 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 3503 | |
| Ratio of female employees in managerial positions metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.171 | |
| All employees calculated based on provisions of act on promotion of womens active engagement in professional life ratio of male employees taking childcare leave metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 1.294 | |
| Regular employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.790 | |
| Non regular employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.684 | |
| All employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.783 | |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00816-000PharmaceuticalsReportableSegmentMember | 101200000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 34985000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 525634500 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 525634500 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 525634500 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 525634500 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | 1 | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 43 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 36 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 440 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 689 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 65 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 28835 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 30109 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | 6 | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 805244 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 183370 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 2938023 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 974779 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 500 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 349586 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 5251508 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 483700 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | 0.0000 | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.1533 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0349 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.5595 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |